Lancashire and South Cumbria
Formulary
Formulary
2 Cardiovascular system
02-05-01 Vasodilator antihypertensive drugs
| Hydralazine |
|
Formulary
|
Tablets 25mg, 50mg
|
 NG106: Chronic heart failure in adults: diagnosis and management |
|
Hypertension
Heart failure (Initiated in hospital or under specialist supervision)| Sildenafil |
|
Formulary
|
Tablets 20mg Tertiary centre only
|
|
MHRA Drug Safety Update Nov 18: Sildenafil (Revatio and Viagra): reports of persistent pulmonary hypertension of the newborn (PPHN) following in-utero exposure in a clinical trial on intrauterine growth restriction |
|
| Sotatercept Winrevair® |
|
Formulary
|
Solution for injection 45 mg, 60 mg
Specialist use only
|
|
NICE TA1161: Sotatercept for treating pulmonary arterial hypertension |
|
|
Links
Enoxaparin for Treatment of Venous Thromboembolism **FOR USE IN THE BLACKPOOL REGION ONLY** - Enoxaparin Shared Care Guideline **FOR USE IN THE MORECAMBE BAY REGION ONLY**
Low Molecular Weight Heparins - Use in Primary care Best Practice Guideline *FOR USE IN PENNINE REGION ONLY* - LSC Hypertension in Adults: Diagnosis and Management
- LSC Patient Pathway for Commencing Inclisiran
- LSC Statin Intolerance Pathway
- LSCMMG: Atrial Fibrillation Pathway for the prevention of stroke and systemic embolism in AF in the absence of valvular heart disease
- LSCMMG: Lipid Management Pathway for Primary Prevention of Cardiovascular Disease
- LSCMMG: Lipid Management Pathway for Secondary Prevention of Cardiovascular Disease
- MHRA Drug Safety Update August 2016: Riociguat (Adempas): not for use in patients with pulmonary hypertension associated with idiopathic interstitial pneumonias
- MHRA Drug Safety Update Nov 18: Sildenafil (Revatio and Viagra): reports of persistent pulmonary hypertension of the newborn (PPHN) following in-utero exposure in a clinical trial on intrauterine growth restriction
- National Pulmonary Hypertension commissioning policy
- National Pulmonary Hypertension commissioning policy
- NG106: Chronic heart failure in adults: diagnosis and management
- NICE NG106: Chronic heart failure in adults: diagnosis and management
- NICE NG136: Hypertension in adults: diagnosis and management
- NICE NG167: COVID-19 rapid guideline: rheumatological autoimmune, inflammatory and metabolic bone disorders
- NICE NG185: Acute Coronary Syndromes
- NICE NG187: Acute heart failure: diagnosis and management
- NICE NG196: Atrial fibrillation: diagnosis and management
- NICE NG203: Chronic kidney disease: assessment and management
- NICE NG95: Recent-onset chest pain of suspected cardiac origin: assessment and diagnosis
- NICE TA1161: Sotatercept for treating pulmonary arterial hypertension
- NICE TA731:Vericiguat for treating chronic heart failure with reduced ejection fraction (terminated appraisal)
- NICE: review of evidence
- Policy and procedure for prophylaxis against, and treatment of, VTE in adult patients **FOR USE IN THE CENTRAL LANCS REGION ONLY**
- Prevention of VTE in Medical Surgical Patients (16 years +) and those requiring lower limb plaster casts/immobilisations **FOR USE IN THE BLACKPOOL REGION ONLY**
- Renal: Enhanced Supportive Kidney Care Guideline